All In Biotech

NDA 022212 · Sandoz

Durezol

Difluprednate · Ophthalmic

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Jun 23, 2008

Approved uses

3

Original approval plus efficacy supplements

Registered trials

23

13 Phase 3, 0 recruiting

FAERS reports

3,862

1,778 serious, 126 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 18, 2026.

Difluprednate ophthalmic emulsion is a corticosteroid indicated for: • The treatment of inflammation and pain associated with ocular surgery. ( 1.1 ) • The treatment of endogenous anterior uveitis. ( 1.2 ) 1.1 Ocular Surgery Difluprednate ophthalmic emulsion is indicated for the treatment of inflammation and pain associated with ocular surgery. 1.2 Endogenous Anterior Uveitis Difluprednate ophthalmic emulsion is indicated for the treatment of endogenous anterior uveitis.

Mechanism: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and may delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DUREZOL · DIFLUPREDNATE 0.05% · EMULSION, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Difluprednate" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • intraocular pressure increased530
  • drug ineffective251
  • eye pain243
  • vision blurred193
  • off label use178
  • eye irritation175
  • cataract158
  • visual impairment155
  • fatigue135
  • headache126
  • therapy partial responder105
  • diarrhoea101

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20063
20076
20085
20096
20109
201129
201252
201368
201480
2015169
2016533
2017578
2018355
2019402
2020338
2021243
2022236
2023256
2024191
2025177
2026124

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Durezol (Difluprednate)

2024 spending

$805K

Beneficiaries

1,541

2,990 claims

Per beneficiary

$522

$42.00 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$629,269
2024$804,791

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.